臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :2830311
	造訪人次 : 32547589 線上人數 : 920 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"oxnard g r"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-04-23T05:56:30Z	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer	Oxnard G.R.;Chih-Hsin Yang;Yu H.;Kim S.-W.;Saka H.;Horn L.;Goto K.;Ohe Y.;Mann H.;Thress K.S.;Frigault M.M.;Vishwanathan K.;Ghiorghiu D.;Ramalingam S.S.;Ahn M.-J.; Oxnard G.R.; CHIH-HSIN YANG; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J.
臺大學術典藏	2020-05-26T09:26:47Z	136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial	Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R.
臺大學術典藏	2020-05-26T09:26:47Z	136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial	Oxnard G.R.;Walding A;Yang L;Kim S.-W;Goto K;Ramalingam S;Saka H;Yu H;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R.
臺大學術典藏	2020-05-26T09:26:46Z	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC	J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.
臺大學術典藏	2020-05-26T09:26:46Z	135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC	J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.

顯示項目 1-7 / 7 (共1頁)
1
每頁顯示[10|25|50]項目